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were included and assessed with respect to their evidence for special subgroups. 
Regulatory guidelines were compared against the IQWIG evaluation methods 
with respect to the handling of subgroups and its impact on the clinical benefit 
assessment. Furthermore GBA decisions and potential price impact with the GKV-
Spitzenverband are taken into account for the pricing impact of new evidence 
with special subgroups based on target profiles developed. Results: Overall, ten 
new compounds were approved by the EMA in the last 2.5 years for which no 
subgroup trials were presented. Regulatory guidelines and IQWIG methods differ 
significantly with respect to subgroup handling from a statistical and health policy 
perspective. Most important clinical trials with a special focus on subgroups of 
interest could even have a negative outcome on the market access of such a com-
pound with respect to subgroup-only reimbursement (in case of positive subgroup 
results) or exclusion of subgroups (in case of negative results) based on target 
profiles included in the analyses. ConClusions: Incentives from a health policy 
and investment decision perspective are low for the pharmaceutical industry in 
terms of research focus towards subgroups of special interest. Further research 
with respect to incentives is needed.
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objeCtives: To identify the extent to which current approaches to clinical devel-
opment, regulatory assessment, and economic evaluation of personalised health 
care drugs in oncology are aligned with real world clinical practice at product 
launch. To identify and critically evaluate alternative approaches that should be 
factored into future clinical development and health technology assessment (HTA) 
planning. Methods: Structured interviews were undertaken with physicians and 
payers (n= 50) to identify the key issues surrounding the phased development and 
early use of personalised health care drugs in oncology. Analogue analyses were 
undertaken, based on “treatment tracking”, to develop a comparison between 
theoretical RCT (randomised control trial) evidence based, licensure aligned, uti-
lisation and that observed in real world clinical practice Gap Analyses identified 
drivers of differences. The utility and limitations of retrospective and prospective 
observational registries in addressing these were explored. Results: Early results 
indicate that the level of unmet need, the magnitude of incremental clinical ben-
efit, the timing of biomarker testing in the treatment algorithm and, increasingly, 
the number and prioritisation of diagnostic tests for an increasing number of dif-
ferent biomarkers are drivers of real world utilisation. Differences exist between 
countries. The greatest differences between theoretical and real world utilisation 
are in markets where decisions are driven by considerations of relative clinical 
effectiveness rather than cost effectiveness. Comparative SWOT analyses were 
developed of current and alternative clinical development, regulatory and health 
technology assessment systems. These highlight areas where improvements in 
approach would be beneficial. ConClusions: Additional evidence sources should 
be used to reinforce the regulatory and health technology assessment of PHC 
products in oncology with the aim of bringing closer alignment between the RCT 
approach to drug development and assessment – and the utilisation and outcomes 
(economic, clinical, and humanistic) seen in real-world clinical practice.
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objeCtives: The overall goal of our project is to adapt an Austrian decision-analytic 
model for the treatment of chronic myeloid leukemia (CML) to the U.S. context. We 
conducted an electronic survey to gain expert knowledge about the state-of-the-
art in CML treatment. Methods: The expert survey was constructed as an online 
questionnaire and contained 14 questions. The questionnaire was developed in col-
laboration with ONCOTYROL project partners and distributed to CML experts at the 
Huntsman Cancer Institute in Utah. Data were generated using Qualtrics and dis-
cussed with experts in order to incorporate the findings into the model. Results: 
Four out of six experts (67%) stated that effectiveness of second-line TKI depends 
on the response to first-line TKI therapy. NCCN and ELN guidelines are the most fre-
quently used guidelines when treating CML patients. Furthermore, expert opinion, 
literature and personal characteristics influence decision making. Patients younger 
than 50, or between 50 and 54 years, most frequently receive stem cell transplanta-
tion after TKI failure. The recently approved TKIs bosutinib and ponatinib are used 
by 17% and 100% respectively. Experts stated that quality of life (QoL) on dasatinib 
is better (17%)/ about the same (50%)/ worse (33%) compared to imatinib. QoL on 
nilotinib is better (17%)/ about the same (83%) in comparison to imatinib. QoL on 
ponatinib is better (17%)/ about the same (67%)/ worse (17%) compared to imatinib. 
Although bosutinib is rarely (67%) used, experts answered that is better (17%) or 
about the same (17%) compared to imatinib. ConClusions: The results provide 
valuable insights into the state-of-the-art of CML treatment in the U.S. context. Due 
to the small sample size and the limitation to the region of Utah, results should 
be interpreted carefully. However, the responses for ponatinib and bosutinib are 
particularly valuable for the model due to lack of QoL and long-term data.
ognized the added benefit claim in 2 cases only. In an additional 2 cases no clear scor-
ing was provided for the QOL outcome and in the remaining 11 cases no additional 
benefit was acknowledged. The main reasons were missing statistical significance 
of results or the submitted QOL data were regarded as not usable. ConClusions: 
In a majority of value dossiers companies included QOL data and also most often 
claimed an added benefit in QOL. However, the assessors have accepted this added 
value in exceptional cases only. In order to get an added value recognized showing 
both statistical and clinical significance of results is required.
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objeCtives: To investigate the feasibility of a online survey using social media 
(facebook) to estimate the willingness to pay (WTP) for a new diagnostic blood 
test to determine the risk of colorectal cancer. According to the approval docu-
ments of the manufacturer the new biomarker test shows a better performance, 
better handling and improved compliance of patients and physicians compared 
to standard fecal occult blood tests (FOBT). Methods: A standardized question-
naire was accompanied by background information on colorectal cancer and 
alternative screening approaches. WTP was asked for in categories (e.g. < 100 or 
> 100 EUR) and maximum values. Other parameters such as age, sex, insurance 
status, income, family history of cancer and risk factors were determined in 
categories. The survey ran for 14 days in November 2012 and was started via 6 
facebook accounts with the possibility of further distribution. Results: Overall 
123 completed questionnaires were submitted anonymously. The average age 
was 24,2 years and in 94% the monthly income was below 1500 EUR due to their 
student status. 68% of the participants had cases of cancer in the family and 
36% knew about the colorectal cancer. The most important quality aspects of 
screening tests for were accuracy (69%), handling (14%), price (11%) and the time 
to result (6%). 24% stated that their WTP is lower than 100EUR and the mean WTP 
for S9 was 271EUR. Higher income, family history of colorectal cancer and private 
insurance status were positively correlated with a higher WTP. ConClusions: 
WTP and patient preference studies via social networks such as facebook are fea-
sible, easy to perform and reveal plausible results. Advantages of online surveys 
in social networks are that the results are gained voluntarily and anonymously 
avoiding interviewer bias. Disadvantages obviously lie in a selection of young 
and healthy populations.
CaNCer – Health Care use & Policy studies
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objeCtives: Recently a major cancer center in the United States decided not to 
offer treatment using a newly launched oncology drug citing comparative effective-
ness and cost as reasons. This study looked at health care consumer opinions about 
the decision to restrict treatment options based on outcomes and price. Methods: 
The nationally representative Truven Health PULSE Healthcare Survey gathered 
responses from 2,615 US households via landline telephone, cell phone or Internet. 
Respondents were asked their opinion regarding a decision by providers not to offer a 
new cancer treatment because it demonstrated the same benefit as an existing drug 
with the same side effects, but its cost was higher. Demographic data were gathered 
and respondents were asked if they are being/have been treated for cancer, and if a 
friend, family member or loved one is being/has been treated for cancer. Results: 
Overall, 40.5% of respondents agreed with the decision; 37.5% disagreed. Agreement 
with the decision varied with the respondents’ exposure to cancer. Those who had 
a family member, friend or loved one with cancer were least likely to agree (36%), 
while those who not only had a family member, friend or loved one with cancer, but 
also had cancer themselves were the most likely to agree (50.8%). Respondents who 
had cancer themselves with no family member, friend or loved one with cancer or 
had no experience with cancer were equally likely to agree with the decision (44%) 
(P< 0.0001). ConClusions: Findings suggest that fear and experience may play roles 
in consumers’ opinions regarding restrictions on cancer medications. Individuals who 
have experienced cancer may place more value on outcomes, side effects, and/or out-
of-pocket costs than those with no personal experience or may have more realistic 
expectations for treatment. Additional research is warranted to better understand the 
drivers of consumer opinion regarding cancer treatment coverage decisions.
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objeCtives: Definition of target profiles for new compounds and lifecycle plan-
ning lead to clinical studies in the context of a clinical trial program. Currently 
subgroups of special interest such as elderly, pediatrics or females/males are nor-
mally not separately included in these research programmes, most of the time 
not even stratified for. The objective of this research is to analyze the inclusion of 
patient-relevant endpoints in special patient subgroups during the clinical trial 
programme which would thereafter increase the pricing opportunity of this new 
compound in the German market. Methods: New oncology therapies which 
were authorized by the European Medicine Agency (EMA) after January 1, 2011 
